Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia.

Nisenbaum LK, Downing AM, Zhao F, Millen BA, Munsie L, Kinon BJ, Adams DH, Gomez JC, Penny MA.

J Pers Med. 2016 Feb 5;6(1). pii: E9. doi: 10.3390/jpm6010009.

2.

Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium.

Young JW, Potter WZ, Riley S, Groeneveld GJ, Kinon BJ, Egan MF, Feltner DE.

Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):5S-10S.

3.

Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.

Szabo ST, Kinon BJ, Brannan SK, Krystal AK, van Gerven JM, Mahableshwarkar A, Sachs GS.

Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):11S-25S.

4.

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia.

Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, Brenner R, Rayle TJ, Nisenbaum L, Zhao F, Gomez JC.

BMC Psychiatry. 2014 Dec 10;14:351. doi: 10.1186/s12888-014-0351-3.

5.
6.

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.

Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez JC.

Schizophr Res Treatment. 2014;2014:758212. doi: 10.1155/2014/758212. Epub 2014 Mar 19.

7.

The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial.

Chen L, Johnston JA, Kinon BJ, Stauffer V, Succop P, Marques TR, Ascher-Svanum H.

BMC Psychiatry. 2013 Nov 28;13:320. doi: 10.1186/1471-244X-13-320.

8.

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia.

Chen L, Ascher-Svanum H, Lawson A, Stauffer VL, Nyhuis A, Haynes V, Schuh K, Kinon BJ.

Neuropsychiatr Dis Treat. 2013;9:815-22. doi: 10.2147/NDT.S43574. Epub 2013 Jun 14.

9.

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.

Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, Walling DP.

BMC Psychiatry. 2013 May 22;13:143. doi: 10.1186/1471-244X-13-143.

10.

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.

Haynes VS, Zhu B, Stauffer VL, Kinon BJ, Stensland MD, Xu L, Ascher-Svanum H.

BMC Psychiatry. 2012 Dec 5;12:222. doi: 10.1186/1471-244X-12-222.

11.

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ.

BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142.

12.

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.

Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D.

Patient Prefer Adherence. 2012;6:521-32. doi: 10.2147/PPA.S25635. Epub 2012 Jul 13.

13.

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia.

Ascher-Svanum H, Brnabic AJ, Lawson AH, Kinon BJ, Stauffer VL, Feldman PD, Kelin K.

Neuropsychiatr Dis Treat. 2012;8:113-8. doi: 10.2147/NDT.S30268. Epub 2012 Mar 15.

14.

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial.

Chen L, Phillips G, Johnston J, Kinon BJ, Ascher-Svanum H, Kollack-Walker S, Succop P, Naber D.

BMC Psychiatry. 2011 Dec 28;11:203. doi: 10.1186/1471-244X-11-203.

15.

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy.

Peng X, Ascher-Svanum H, Faries DE, Stauffer VL, Kollack-Walker S, Kinon BJ, Kane JM.

Clinicoecon Outcomes Res. 2011;3:79-87. doi: 10.2147/CEOR.S16859. Epub 2011 Apr 20.

16.

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.

Ruberg SJ, Chen L, Stauffer V, Ascher-Svanum H, Kollack-Walker S, Conley RR, Kane J, Kinon BJ.

BMC Psychiatry. 2011 Feb 9;11:23. doi: 10.1186/1471-244X-11-23.

17.

The heterogeneity of antipsychotic response in the treatment of schizophrenia.

Case M, Stauffer VL, Ascher-Svanum H, Conley R, Kapur S, Kane JM, Kollack-Walker S, Jacob J, Kinon BJ.

Psychol Med. 2011 Jun;41(6):1291-300. doi: 10.1017/S0033291710001893. Epub 2010 Oct 7.

18.

Predictors of switching antipsychotic medications in the treatment of schizophrenia.

Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ.

BMC Psychiatry. 2010 Sep 28;10:75. doi: 10.1186/1471-244X-10-75.

19.

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Ball DE, Kinon BJ.

BMC Psychiatry. 2010 Jan 28;10:11. doi: 10.1186/1471-244X-10-11.

20.

Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.

Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM.

Neuropsychopharmacology. 2010 Jan;35(2):581-90. doi: 10.1038/npp.2009.164.

Supplemental Content

Loading ...
Support Center